News | December 14, 2023
Pfizer expects 2024 revenue between US$ 58.5 to US$ 61.5 billion
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Need to harmonize traditional and modern medicine to combat alarming health problems
Contracts are related to a $487 million biotech expansion project in Denmark and first phase of a new life sciences production facility valued at $574 million in Central U.S.
_256_384.jpg)
HMD had supplied 921.7 million syringes to the Government of India to facilitate over 2.2 billion Vaccination in India till date
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
Subscribe To Our Newsletter & Stay Updated
